These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36710421)

  • 41. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
    J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
    Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
    Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
    Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
    Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
    Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
    Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
    J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in venous clot structures between hemophilic mice treated with emicizumab
    Sefiane T; Maynadié H; Ettingshausen CE; Muczynski V; Heiligenstein X; Dumont J; Christophe OD; Denis CV; Casari C; Lenting PJ
    Haematologica; 2024 Jun; 109(6):1836-1848. PubMed ID: 38058210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
    Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
    Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
    Augustsson C; Norström E; Lind V; Martin M; Astermark J; Strandberg K
    Haemophilia; 2021 May; 27(3):494-500. PubMed ID: 33866649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
    Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
    Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
    Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
    J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
    Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
    Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.